Investment firm Antipodes Global Value Strategy disclosed in its Q2 2026 letter to investors that it has exited its position in French pharmaceutical and healthcare company Sanofi (Nasdaq: SNY). The strategy cited a series of setbacks in Sanofi's R&D pipeline as the reason for the divestment, which impacted its confidence in Sanofi's ability to compete effectively after the exclusivity period for Dupixent ends. It also noted that Sanofi's R&D transformation could take several years and that the company has recently underperformed in business development. Sanofi's stock closed at $42.78 on August 5, 2026, down 2.55% over the past month and 9.80% over the past 52 weeks.